APGE — Apogee Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Apogee To Host Call To Report Interim Results From Phase 1b Trial Of APG777 In Patients With Mild-To-Moderate Asthma
Brief: Apogee Therapeutics Provides Pipeline Progress
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation
U.S. STOCKS ON THE MOVE-Whirlpool, IREN, Cidara
Apogee Therapeutics falls after $300 mln stock offering priced
Brief: Apogee Therapeutics, Inc. Announces Pricing Of $300 Million Underwritten Public Offering
Brief: Apogee Therapeutics Announces Proposed Underwritten Public Offering
Apogee Therapeutics drops on stock offering launch
U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust
Brief: Apogee Therapeutics to Present 16-Week Phase 2 Data on APG777 for Atopic Dermatitis at EADV 2025
Apogee Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Apogee Therapeutics Provides Pipeline Progress And Reports Second Quarter 2025 Financial Results
Apogee Therapeutics falls after eczema drug shows lower response rate than rival treatments
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
U.S. STOCKS ON THE MOVE-U.S. Bancorp, IonQ, BlackRock
U.S. STOCKS ON THE MOVE- Cogent Biosciences, Sandstorm Gold, Tesla
U.S. STOCKS ON THE MOVE-Tesla, Constellation Brands, KalVista Pharma
Apogee Therapeutics jumps after eczema drug meets main goal in mid-stage study
Apogee Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary